Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NYSE
Website: medtronic.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2024 | $83.00 | Sell | Goldman |
7/19/2023 | $90.00 | Neutral | Robert W. Baird |
6/30/2023 | $106.00 | Buy | CL King |
5/30/2023 | $104.00 | Equal-Weight → Overweight | Morgan Stanley |
4/24/2023 | $77.00 → $100.00 | Equal Weight → Overweight | Wells Fargo |
3/29/2023 | $127.00 → $79.00 | Buy → Sell | UBS |
1/9/2023 | $102.00 → $89.00 | Outperform → Sector Perform | RBC Capital Mkts |
11/23/2022 | $108.00 → $85.00 | Buy → Neutral | Citigroup |
11/23/2022 | $106.00 → $85.00 | Outperform → Perform | Oppenheimer |
11/16/2022 | $85.00 | Buy → Hold | Deutsche Bank |
DUBLIN, June 26, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc. "On behalf of our employees, our executive committee and our board of directors, I want to thank Karen for her leadership over the last eight years. I am personally grateful to Karen for her support through my transition to CEO, navigating the pandemic and delivering a new operating model for the company. We wish her all the best as she takes on the next chapter of her career," said Geoff Martha, Medtronic chairman and chief executive
With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep DUBLIN and ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tac
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras
TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) as its "Stock to Study" and Medtronic PLC (NYSE:MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use. "With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors counsels everyday Americans seeking long term wealth to focus on fundamentals and learn to earn," said Ken Zendel, CEO of National Association of Investors Corp. (NAIC), the parent organiza
DUBLIN, June 6, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 45th annual Goldman Sachs global healthcare conference on Tuesday, June 11, 2024. Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the company beginning at 10:40 a.m. EDT (9:40 a.m. CDT). A live webcast of the Q&A session will be available on June 11, 2024, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the Q&A session will be available on the same webpage later in the day. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered i
DUBLIN, June 3, 2024 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE:MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €850,000,000 principal amount of 3.650% senior notes due 2029, €850,000,000 principal amount of 3.875% senior notes due 2036, €600,000,000 principal amount of 4.150% senior notes due 2043, and €700,000,000 principal amount of 4.150% senior notes due 2053 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A., a wholly-owned subsidiary of the Company and the indire
DUBLIN, May 29, 2024 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE:MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the "Offering") of €850,000,000 principal amount of 3.650% senior notes due 2029, €850,000,000 principal amount of 3.875% senior notes due 2036, €600,000,000 principal amount of 4.150% senior notes due 2043, and €700,000,000 principal amount of 4.150% senior notes due 2053 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A., a wholly-owned subsidiary of the Company and the indirect parent of
Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organicFY24 GAAP diluted EPS of $2.76; non-GAAP dilute
Award recognizes the commitment of Medtronic to revolutionizing diabetes care DUBLIN, May 20, 2024 /PRNewswire/ -- Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation for good. This is the fourth consecutive year Medtronic has been recognized on the list, receiving previous honors for GI Genius™, the Micra™ leadless pacemaker and Medtronic LABS. "The recognition of the MiniMed™ 780G system as a World Changing Idea reflects our commitme
HRS late breaking data: SPHERE Per-AF trial demonstrates novel all-in-one system delivers exceptional results, plus increased efficiency and improved quality of life DUBLIN and BOSTON, May 17, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) piv
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
DUBLIN, June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023. "We are thrilled to have Greg Lewis join our Board. His background in financial leadership across multiple industries will be a strong asset as Medtronic pushes forward a comprehensive transformation that will set us up to deliver on durable growth," said Geoff Martha, Chairman and CEO of Medtronic. "I'm honored to join the Medtronic Board of Directors. I believe in the company's mission to al
Recently Retired Medtronic Chief Medical Officer and Chief Scientific Officer with Deep Expertise in Stroke Treatment DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023. Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee. Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009. Before joining Medtronic, he was
DUBLIN, June 27, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022. Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board. "We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha, Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the
Que Dallara joins as EVP & President, Diabetes Mike Marinaro named President, Surgical Robotics Dr. Kweli Thompson named President, Cardiac Rhythm Management DUBLIN, March 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and capabilities and creating opportunities for internal talent. "The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three Operating Unit President roles some of the most important a
MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D
Company announces new appointment of US Vice President of Sales Palliare, an emerging company with the vision to create a safer operating room, today announced the closing of an oversubscribed $8 million Series A funding round. The round was led by leading European Life Sciences Venture Capital firm Seroba Life Sciences, with participation from Luxembourg-based SCM AD Ventures, Western Development Commission, and several private investors. The funds will be used to support US commercial launch activities related to Palliare's EVA15 insufflator and smoke evacuation system, as well as new Research & Development activities. There has been growing awareness of the hazardous nature of surgical
EDEN PRAIRIE, Minn., April 27, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB:NMTC, NeuroOne or the Company))), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Hijaz Haris, as its Vice President of Marketing. Mr. Haris joins NeuroOne from Medtronic plc, (NYSE:MDT) where he was Senior Global Marketing Director for Brain Modulation. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Hijaz's appointment strengthens our executive leadership team and addresses a critical gap we had entering 2021. We believe his broad experience in the n
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume NVAX CALL TRADE BEARISH 06/28/24 $15.00 $129.4K 1.0K 2.4K INSM PUT TRADE BULLISH 01/1
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population. Tackling hyperglycemia to improve long-term health with type 1 diabetes Among the burdens of living wit
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume A PUT TRADE BEARISH 07/19/24 $130.00 $620.0K 423 1.0K ISRG CALL SWEEP BEARISH 07/19/24 $345.00 $203.3
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Royalty Pharma plc (NASDAQ:RPRX) Dividend Yield: 3.06% B of A Securities analyst Geoff
Medtronic's (NYSE:MDT) short percent of float has risen 10.38% since its last report. The company recently reported that it has 15.33 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i
Medtronic Plc (NYSE:MDT) has initiated a recall for some versions of its StealthStation S8 application. The FDA deemed software recall as Class I, the most serious kind. The medical device giant is recalling the StealthStation S8 Application Versions 1.2.0, 1.1.0, 1.0.3, 1.0.2, and 1.0.1 after customer complaints about a software error that caused numbers or letters to be missing from the displayed text and replaced by a space in either the “distance to target” or “tip stop point” display during navigation. The missing digit may cause the mechanical depth stop to be set too short or too long, causing the surgeon to use an incorrect measurement to place the biopsy tip stop during naviga
- Reuters
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.
Goldman initiated coverage of Medtronic with a rating of Sell and set a new price target of $83.00
Robert W. Baird initiated coverage of Medtronic with a rating of Neutral and set a new price target of $90.00
CL King initiated coverage of Medtronic with a rating of Buy and set a new price target of $106.00
Morgan Stanley upgraded Medtronic from Equal-Weight to Overweight and set a new price target of $104.00
Wells Fargo upgraded Medtronic from Equal Weight to Overweight and set a new price target of $100.00 from $77.00 previously
UBS downgraded Medtronic from Buy to Sell and set a new price target of $79.00 from $127.00 previously
RBC Capital Mkts downgraded Medtronic from Outperform to Sector Perform and set a new price target of $89.00 from $102.00 previously
Citigroup downgraded Medtronic from Buy to Neutral and set a new price target of $85.00 from $108.00 previously
Oppenheimer downgraded Medtronic from Outperform to Perform and set a new price target of $85.00 from $106.00 previously
Deutsche Bank downgraded Medtronic from Buy to Hold and set a new price target of $85.00
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G - Medtronic plc (0001613103) (Filed by)
SC 13G - Medtronic plc (0001613103) (Filed by)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
8-K - Medtronic plc (0001613103) (Filer)
10-K - Medtronic plc (0001613103) (Filer)
IRANNOTICE - Medtronic plc (0001613103) (Filer)
144 - Medtronic plc (0001613103) (Subject)
CERT - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
FWP - Medtronic plc (0001613103) (Subject)
SD - Medtronic plc (0001613103) (Filer)
8-K - Medtronic plc (0001613103) (Filer)
Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organicQ4 GAAP diluted earnings per share (EPS) of $0.49; non-GAAP diluted EPS of $1.46FY24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organicFY24 GAAP diluted EPS of $2.76; non-GAAP dilute
Board authorizes $5 billion for share repurchases DUBLIN, March 7, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on April 12, 2024, to shareholders of record at the close of business on March 22, 2024. In addition to approving the dividend, the board today
Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance DUBLIN, Feb. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key Highlights Revenue of $8.1 billion increased 4.7% as reported and 4.6% organicGAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.30Raises FY24 organic revenue growth and EPS guidanceCompany provides portfolio management update on Patient Monitori
DUBLIN, Dec. 7, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on January 12, 2024, to shareholders of record at the close of business on December 20, 2023. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartere
Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal year guidance DUBLIN, Nov. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8.0 billion increased 5.3% as reported and 5.0% organicGAAP diluted earnings per share (EPS) of $0.68; non-GAAP diluted EPS of $1.25Underlying business fundamentals are strong with broad-based, diversified growth coming from multiple businesses and geographiesCompany increases FY24 organic reven
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc
DUBLIN, Aug. 17, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company's cash dividend for the second quarter of fiscal year 2024 versus the prior year, raising the quarterly amount to $0.69 per ordinary share. This quarterly declaration is consistent with the first quarter dividend announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on October 13, 2023, to shareholders of record at the close of business on September 22, 2023. About MedtronicBo
Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN, May 25, 2023 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2023, which ended April 28, 2023. Fourth Quarter (Q4) Key Highlights Q4 revenue of $8.5 billion increased 5.6% as reported and organic, ahead of expectations Q4 GAAP diluted EPS of $0.88 decreased 20%; non-GAAP diluted EPS of $1.57 increased 3% in the quarter, ahead of expectations Q4 revenue growth acceleration was broad-based, driven by procedure volume recovery, supply improvements, and innovative product introductions Strength in international markets
DUBLIN, March 2, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2022. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 45 consecutive years. The dividend is payable on April 14, 2023, to shareholders of record at the close of business on March 24, 2023. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc,
Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN, Feb. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights Revenue of $7.7 billion was flat as reported and increased 4.1% organic, ahead of expectationsGAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectationsCompany increases FY23 organic revenue growth and EPS outlook"We returned to mid-single digit organic growth as we execute our strategy with urgency." -Geoff Martha, Chairma
3 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)